Cross Icon
Let’s talk.
Reach us anytime via hello@weguide.health
Let’s talk about
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Post Market Clinical Follow Up (PMCF): How MedTech Teams Plan and Run PMCF Surveys, Registries and Studies

PMCF is how device manufacturers keep proving safety and performance after launch. This guide covers the EU rules, the PMCF plan, FDA and TGA equivalents, and how to run surveys and registries that hold up to review.
Post market clinical follow up methods ranked by evidence: clinical investigation, device registry, PROM survey, user survey
Author
Written by Thijs Sondag
Chief Product Officer
November 16, 2026
November 16, 2026
25 min read
Fact checked by WeGuide Editorial Team

Post market clinical follow up (PMCF) is the continuous EU MDR process in which a device manufacturer proactively collects and evaluates clinical data from its CE marked device in real use. It confirms safety and performance over the device's expected lifetime, keeps identified risks acceptable and detects emerging risks early, as set out in Annex XIV Part B of Regulation (EU) 2017/745.

The definition is the easy part. The hard part is turning a PMCF plan into data a notified body will accept, year after year. This guide covers the PMS and PMCF document map, a methods table tied to the MDCG evidence hierarchy, PMCF surveys and device registries, and the FDA and TGA equivalents.

Key Takeaways

  • PMCF updates the clinical evaluation. It sits inside post market surveillance (PMS), is written into a PMCF plan, and is reported in a PMCF evaluation report that feeds the CER and the PSUR.
  • A plan or a justification. Every PMS plan needs a PMCF plan or a documented reason why PMCF is not applicable (MDR Annex III 1.1(b)).
  • Method choice follows the evidence gap. General surveys rank 8 in the MDCG 2020-6 hierarchy, high quality surveys can reach rank 4, high quality registries rank 3, and high quality clinical investigations rank 1 or 2.
  • No statistical rationale, no credit. MDCG 2020-7 says retrospective surveys without a statistical rationale "are not acceptable", so endpoints and sample size come first.
  • Execution decides data quality. Validated PROMs, electronic delivery, multilingual consent and retention design separate usable PMCF data from survey noise.

What Is Post Market Clinical Follow Up (PMCF)?

PMCF is a continuous process that updates a device's clinical evaluation. It's addressed in the manufacturer's post market surveillance plan, and its results flow back into the clinical evaluation and the risk management file. The EU MDR gives the PMCF plan five aims (Annex XIV Part B, section 6.1):

  • Confirm the safety and performance of the device throughout its expected lifetime.
  • Identify previously unknown side effects, and monitor the side effects and contraindications already identified.
  • Identify and analyze emergent risks on the basis of factual evidence.
  • Ensure the continued acceptability of the benefit risk ratio.
  • Identify possible systematic misuse or off label use, so the intended purpose can be confirmed as correct.

The idea isn't only European. The International Medical Device Regulators Forum treats PMCF studies as an international concept in IMDRF MDCE WG/N65 FINAL:2021, which replaced GHTF/SG5/N4:2010. In vitro diagnostics have a parallel process under the IVDR, post market performance follow up (PMPF). This guide covers devices only.

PMCF vs Post Market Surveillance (PMS): How the Documents Fit Together

Post market surveillance is the manufacturer's whole system for proactively collecting and reviewing experience from the devices it has placed on the market (MDR Article 2(60)). PMCF is the part of that system that produces clinical data. Complaints, trend reporting and vigilance sit in PMS. The clinical questions left open by the clinical evaluation sit in PMCF.

The documents are where teams get confused, because each has its own audience and update rule.

DocumentWhat it isWho needs itUpdate ruleSource
PMS planThe plan for collecting and using post market data, part of the technical documentationAll device classesKept current as part of the PMS systemMDR Article 84, Annex III
PMCF planMethods, objectives and timelines for proactive clinical data collectionAll classes, unless a justification replaces itActivity timelines defined "quarterly or at least yearly"Annex XIV Part B section 6, MDCG 2020-7
PMCF evaluation reportAnalysis of PMCF results and their impact on the device's documentationEvery device with a PMCF planAt least annually for class III and implantable devices, otherwise on the plan's scheduleAnnex XIV Part B section 7, Article 61(11), MDCG 2020-8
PMS reportSummary of PMS results and any corrective actionClass I"Updated when necessary"Article 85
PSURPeriodic safety update report, including "the main findings of the PMCF"Class IIa, IIb and IIIClass IIa: when necessary and at least every two years. Class IIb and III: at least annuallyArticle 86, MDCG 2022-21
Clinical evaluation report (CER)The manufacturer's evaluation of clinical evidence for the deviceAll classesUpdated throughout the life cycle with PMCF dataArticle 61(11)

Read the table as a loop: PMCF activities generate data, the evaluation report analyzes it, the conclusions update the CER and risk management, and the main findings go into the PSUR. Under Annex XIV Part B section 8, if PMCF shows a need for preventive or corrective action, the manufacturer has to act on it.

These update rules may change. In December 2025 the European Commission proposed a targeted MDR revision (COM(2025) 1023) that would let manufacturers put PMCF findings directly into the updated clinical evaluation report, with no separate PMCF evaluation report, and would move class IIb and III PSURs to the first year after certification and every two years after that. It's still a proposal before the European Parliament and the Council, so the current MDR rules apply until an amendment is adopted.

The EU added a new reference point in December 2025 as well. MDCG 2025-10 is the MDCG's general guidance on the post market surveillance system for medical devices and IVDs. It describes the PMCF plan as "an integral part of the PMS plan", and it lists customer surveys and searches of device registers or registries among the data sources a PMS system can draw on.

When Is PMCF Required, and When Is a Justification Enough?

PMCF is the default for every device class. Annex III section 1.1(b) of the MDR requires the PMS plan to include a PMCF plan "or a justification as to why a PMCF is not applicable". MDCG 2025-10 repeats the point: if the manufacturer decides no specific PMCF activities are needed, a justification is required.

A justification has to be reasoned and documented. In practice it rests on the device's risk, whether it's a well established technology, and whether existing clinical data already cover the residual risks.

Two situations make a justification hard to sustain:

  • Class III and implantable devices without pre market investigations. Where clinical investigations weren't performed under the Article 61(4) exemption, MDCG 2020-7 says "the PMCF plan shall include post market studies to confirm the safety and performance of the device."
  • Legacy devices.MDCG 2020-6, the guidance on clinical evidence for devices previously CE marked under the old directives, says class III and implantable legacy devices that are not well established technologies need clinical data "as a minimum at level 4". It adds: "Reliance solely on complaints and vigilance is not sufficient."

The PMCF Plan and PMCF Evaluation Report: What MDCG 2020-7 and 2020-8 Ask For

A PMCF plan names each activity, why it's needed, how it will run and when results will be reported. The MDR sets the minimum content, and two MDCG templates give the structure.

What goes into a PMCF plan

Annex XIV Part B section 6.2 of the MDR lists the minimum content, items (a) to (h). Use it as your PMCF checklist:

  1. General methods and procedures, such as gathering clinical experience, user feedback and screening of scientific literature.
  2. Specific methods and procedures, such as "evaluation of suitable registers or PMCF studies".
  3. A rationale for why those methods suit the objectives.
  4. A reference to the relevant parts of the clinical evaluation report and to risk management.
  5. The specific objectives the PMCF will address.
  6. An evaluation of clinical data on equivalent or similar devices.
  7. References to relevant common specifications, harmonised standards and guidance.
  8. A detailed and adequately justified time schedule.

MDCG 2020-7, the "Post-market clinical follow-up (PMCF) Plan Template" (April 2020), turns that list into sections A to G, from manufacturer details and device description to PMCF activities, equivalent devices, standards and the date of the first evaluation report.

Section C carries the work. For each activity, the template asks where the need came from (the notified body, the CER, PMS or risk management), the aim and the rationale. It also asks for known limitations, "such as for example incomplete follow up, missing data", and timelines "defined quarterly or at least yearly".

The rationale must cover sample size, timescales, endpoints, comparator, study design and sources of bias. MDCG 2020-7 is blunt about the weakest version: "retrospective surveys with no justification other than 'this should demonstrate the expected quality of evidence that we require,' but without showing a statistical rationale, are not acceptable."

The PMCF evaluation report (PMCF report) under MDCG 2020-8

The PMCF evaluation report is where the plan's results land. MDCG 2020-8, the PMCF Evaluation Report Template (April 2020), uses seven sections, A to G. Two carry the weight: section C, "Activities undertaken related to PMCF: results", and section E, "Impact of the results on the technical documentation". Section G records the conclusions.

Those conclusions aren't a filing exercise. Under Annex XIV Part B section 8, they must feed the clinical evaluation and risk management, so a report that doesn't say what changed in the CER or the risk file will draw questions.

PMCF Methods Compared: Literature, User Feedback, Surveys, Registries and PMCF Studies

The right PMCF activity is the one that can close the evidence gap named in your CER. The table maps the methods in MDCG 2020-7 to the evidence hierarchy in Appendix III of MDCG 2020-6. That hierarchy was written for legacy devices, but it's the clearest published ranking of clinical data sources under the MDR.

MethodGeneral or specific (Annex XIV 6.2)What it producesMDCG 2020-6 rankWhen it can be enoughMain weakness
Literature screeningGeneralPublished data on the device (data on similar devices is rank 6, supportive only)Usually 4 ("Many literature sources fall into this category")Well established devices with relevant literaturePublication bias, time lag
User feedback and complaintsGeneralSafety trends and signals7 (complaints and vigilance)Supportive onlyUnder reporting
General user or HCP surveysGeneralSatisfaction and perceived performance8 ("Proactive PMS data, such as that derived from surveys")Low risk devices with no open clinical questionsRecall bias, low response
High quality patient surveys with validated PROMsGeneral, run to study standardsQuantified outcomes at set timepointsCan reach 4 ("High quality surveys may also fall into this category")Gaps that need quantified outcomesNeeds a statistical rationale and complete follow up
Device registry (own or national)SpecificLong term performance, revisions, rare events3 when high qualityLong term questions for implants and higher risk devicesRepresentativeness and data quality
PMCF study or investigationSpecificProspective, pre specified endpoints1 or 2 for high quality investigationsClass III and implantable gaps, Article 61(4) casesCost, time, Article 74(1) notification if burdensome
RWE analyses of existing dataListed in MDCG 2020-7Outcomes from routine care dataDepends on the sourceWhen data are "of sufficient quality and come from reliable data sources"Missing variables

Two patterns stand out. The cheap general methods sit low in the hierarchy, and MDCG 2020-6 says reliance solely on complaints and vigilance is not sufficient for class III and implantable legacy devices. And the gap between rank 8 and rank 4 for surveys is mostly about design, not cost. A survey with validated instruments, defined timepoints and a statistical rationale is a different evidence source from a satisfaction questionnaire.

So choose by the gap. Unknown long term revision rates point to a registry. Unproven patient reported function at 12 months points to a structured PROM survey or a PMCF study. A suspected off label use pattern points to case report review and targeted user surveys.

Run a product or device registry on one platform

Consent, validated PROMs, reminders and wearable data in a registry participants complete on their own phones.

Explore device registries

How to Run PMCF Surveys That Produce Usable Clinical Data

A PMCF survey produces usable clinical data when it collects quantified, patient level outcomes with validated instruments, on the plan's schedule, from enough participants to answer a stated question.

Patient surveys or HCP surveys

Patient surveys capture what only the patient can report: pain, function, symptoms and quality of life. HCP surveys, completed by the treating clinician per case, capture clinical findings and complications. Many PMCF plans need both.

For the evidence rank, what matters is patient level, quantified outcomes versus general opinion. A clinician's view that the device performs well is rank 8 material. A case level form that records a defined complication at a defined timepoint, for each patient, starts to look like rank 4.

Use validated instruments, not homemade questions

Validated patient reported outcome measures (PROMs) give reviewers known measurement properties and comparable results from other devices. Homemade questions don't.

Device teams usually reach for a condition specific measure plus a generic one. For knee replacement, the KOOS JR is a common choice, with HOOS as the hip equivalent. Cardiac device teams often use the KCCQ, and EQ-5D is the usual generic quality of life measure. Upper limb devices often use DASH, and urology devices IPSS.

One caution: licensing terms differ by instrument. Some, such as EQ-5D and KCCQ, need a license for commercial use, and others are free to use but can't be altered without the developer's permission. Check each instrument's terms with the rights holder and budget for licenses early. For collecting PROMs and PREMs alongside one another, see PROMs and PREMs collection.

Electronic delivery and BYOD

Electronic PROMs are an accepted route. A meta analysis of 72 equivalence studies by Muehlhausen and colleagues found a pooled correlation of 0.88 between paper and electronic scores. A later review by Byrom and colleagues concluded that best practice migration is enough to show equivalence. That also holds for bring your own device (BYOD) studies, if a minimum device specification is ensured and the instrument uses standard response scales.

That matters for PMCF, where participants are spread across clinics and countries. Collecting outcomes on the participant's own phone removes transcription, timestamps every entry and makes follow up at 6, 12 and 24 months practical. An ePRO form builder with built in validation and one form for every supported language cuts entry errors, and direct data capture from participants keeps the record at its source.

Statistical rationale and sample size

MDCG 2020-7 asks for a statistical justification of the expected quality of outcomes, in light of the residual risks. Before launch, define the primary endpoint, the timepoint, the precision you need (for example, the width of a confidence interval around a complication rate) and the expected loss to follow up. Then size the sample and document the reasoning in section C of the plan.

Response and retention by design

Response rates decide whether a survey reaches its planned precision. Schedule each questionnaire to the plan's follow up timepoints, send reminders by app notification, SMS and email, and keep each one as short as the endpoints allow. Track completion per timepoint during the study, not at the end, while gaps can still be closed.

Consent and multilingual delivery

PMCF participants need valid informed consent, in their own language, and a protocol change can mean every active participant has to consent again. WeGuide offers remote eConsent with version control, reconsent tracking and an audit trail. For the wider picture, see eConsent in clinical trials.

Translated PROMs need more than translation. They need linguistic validation of translated PROMs, and many instrument owners supply approved language versions. WeGuide runs multilingual surveys and consent: the INHERIT COVID-19 study ran on WeGuide in ten languages.

Adverse event triage

Any patient survey can surface a serious incident. The PMCF protocol needs a standard operating procedure that routes those reports into the manufacturer's vigilance process, with clear rules for free text answers. The reporting itself stays with the manufacturer's PMS process.

A data collection tool can flag and forward. It doesn't replace vigilance.

Using Device Registries and Real World Evidence for PMCF

Registries are one of the two examples of specific PMCF methods the MDR gives: "evaluation of suitable registers or PMCF studies". MDCG 2020-7 allows a manufacturer device registry to be named in the plan, with "a pre-specification of what quality and quantity data" will be collected, based on the device's risk. The plan can also evaluate suitable national public registries.

A registry doesn't earn rank 3 in MDCG 2020-6 unless it's high quality. The guidance asks four questions, and they make a good design checklist for a product registry:

  • Is there sufficient evidence of the quality of the data the registry collects?
  • Are the devices adequately represented?
  • Are the data appropriately stratified?
  • Are the endpoints appropriate to the safety, performance and endpoints in the clinical evaluation plan?

PROMs belong inside device registries, and arthroplasty registries show how. A survey of international arthroplasty registries by Bohm and colleagues found that 15 of the 25 responding registries collected a generic PROM, most often EQ-5D, and 16 collected joint specific PROMs, most often KOOS and HOOS. Most collected them within 3 months before and 1 year after surgery. The authors' recommendations on timing, attrition and representativeness apply just as well to a PMCF registry.

Real world evidence is gaining ground as EU clinical evidence. In a mixed methods study, McDermott and Kearney found that RWE studies give legacy device manufacturers a way to bridge clinical evidence gaps under the MDR, supplementing data from pre and post market investigations. For a longer view, see patient registries and real world evidence and how to build a patient registry.

Where activity or heart rate is a relevant outcome, wearable data for objective follow up can strengthen a registry. WeGuide has a native Garmin integration, which collects raw accelerometer and gyroscope data at 25 Hz on supported models, and reads Apple Health (HealthKit) and Health Connect for other devices. It also runs product and post market registries that follow patients on a therapy or device to generate real world evidence.

Outside the EU: FDA Section 522, Post Approval Studies and TGA Post Market Duties

The FDA and the TGA require post market evidence too, but neither uses a PMCF plan. The FDA orders specific studies for specific devices. The TGA centers post market duties on sponsor reporting and annual reports for higher risk devices.

RegulatorMechanismWhich devicesTriggerDuration or reportingSource
EUPMCFAll classesPMS plan must include a PMCF plan or a justificationEvaluation report at least annually for class III and implantables, PSUR cycle by classEU MDR
US FDASection 522 postmarket surveillanceClass II or class III devices meeting one of four criteriaFDA orderProspective surveillance up to 36 months unless the manufacturer agrees to longerFDA 522 program, 21 CFR 822
US FDAPost approval study (PAS)PMA and HDE devicesRequired at approvalCondition of approval, and failure to comply can be grounds to withdraw approvalFDA post approval studies
Australia TGASponsor post market obligationsAll ARTG included devices, with annual reports for Class III and Class IIb implantable devicesInclusion in the ARTGAdverse event reporting to IRIS, plus annual reports for the first three yearsTGA guidance

United States. The FDA's 522 program applies to class II or class III devices that meet one of four criteria. Failure would likely have serious adverse health consequences, the device is expected to have significant use in pediatric populations, it's intended to be implanted for more than one year, or it's life sustaining or life supporting and used outside a user facility.

21 CFR Part 822 defines postmarket surveillance as "the active, systematic, scientifically valid collection, analysis, and interpretation of data or other information about a marketed device". Under it, FDA can order prospective surveillance for up to 36 months. Post approval studies are attached to PMA and HDE approvals as conditions of approval. Mandatory adverse event reporting under 21 CFR Part 803 runs alongside both, and Kramer and colleagues compare how the US and EU systems differ.

For registry and real world data in US submissions, the reference is FDA's final guidance on real world evidence for medical devices, issued in December 2025. It supersedes the 2017 version, so check which one your SOPs cite.

Australia. The TGA's guidance on post market responsibilities (last updated March 2026) makes reporting adverse events to IRIS an automatic condition of inclusion in the ARTG for sponsors. It requires annual reports for the first three years after a Class III, Class IIb implantable or Class 4 IVD device is included. The manufacturer investigates problems and takes corrective action. In short, the Australian framework is built around sponsor reporting rather than a PMCF plan.

PMCF Studies and Trials: When Follow Up Becomes a Clinical Investigation Under ISO 14155:2026

A PMCF study is a structured clinical study of a CE marked device used within its intended purpose. MDCG 2020-7 lists examples that range from extended follow up of patients from the pre market investigation to new clinical investigations within the intended use and retrospective studies. The plan has to summarize the design, sample size, endpoints and inclusion and exclusion criteria.

Some PMCF studies are formal clinical investigations. Under MDR Article 74(1), when a PMCF investigation would submit participants to procedures additional to normal use that are invasive or burdensome, the sponsor must notify the Member States concerned at least 30 days before it starts. At that point a "PMCF trial" is a regulated clinical investigation, not a data collection exercise.

The good clinical practice standard for those studies is ISO 14155:2026, the fourth edition, published in March 2026. It replaces the 2020 edition, which ISO has withdrawn. It applies, where relevant, to post market clinical investigations too, so update templates that still cite the 2020 edition.

Data Quality and Audit Readiness: What to Ask a PMCF Data Vendor

A PMCF data platform should show, for any data point, who entered it, when, and under which consent and instrument version. These questions test that.

QuestionWhy it matters for PMCF
Is there an audit trail on every data point and every consent version?Reviewers trace results back to source and consent
How does the platform support data integrity principles such as ALCOA+ data integrity?PMCF data feed the CER, so they need to be attributable and complete
Which validated instruments are available, and who holds the licenses?Unlicensed PROM use creates legal and data risks
Can forms and consent run in every language the plan needs?Multi country plans need translated, validated versions
How are eConsent versions and reconsent handled?Protocol amendments must reach every active participant
Where is participant data hosted, and can it meet your GDPR transfer assessment?EU participant data has transfer rules
Which information security certification does the vendor hold (for example ISO 27001)?Independent evidence of security controls
Can data be exported to your EDC and statistics tools?The evaluation report is built from analysis ready data
Is wearable data native or aggregated through Apple Health or Health Connect?Provenance affects what you can claim about the measure
How do safety signals reach your vigilance process?Serious incidents have reporting deadlines
How long does configuration take?PMCF timelines are fixed in the plan

For a broader version of this list, see the eCOA vendor selection checklist.

Where WeGuide fits. WeGuide is a patient engagement and data collection platform for clinical research and care: screening, eConsent, ePRO/PROMs, wearable data and patient registries, on participants' own phones. On the MedTech side, it brings patient feedback, reported outcomes and relevant health data together, for your own outcome reporting or post market clinical follow up. WeGuide is TGA registered Class I medical device software (ARTG 355337) and ISO 27001 certified, and it supports GDPR requirements.

It's the participant data layer, not an EDC, a monitoring or literature review tool, or a complaint handling or vigilance system. Raw sensor data comes from supported Garmin devices only. Participant data can flow into the sponsor's EDC: WeGuide integrates with REDCap through the REDCap API, and also connects to Castor and Medidata Rave.

Setup typically takes two to four weeks of configuration. Read more about WeGuide for MedTech teams.

Putting Your Post Market Clinical Follow Up Plan Into Practice

Post market clinical follow up works best as an ongoing evidence program, not an annual paperwork cycle. Start from the gaps in the CER and the risk file, write the statistical rationale before the first questionnaire goes out, and collect validated, licensed PROMs on the plan's schedule. Close the loop in each PMCF evaluation report by stating what changed, and track MDCG 2025-10, FDA's December 2025 RWE guidance, ISO 14155:2026, and the progress of the Commission's proposed MDR revision.

Frequently Asked Questions

What is PMCF in medical devices?

PMCF, or post market clinical follow up, is the continuous EU MDR process (Annex XIV Part B) in which a manufacturer proactively collects clinical data from its CE marked device in real use. The results confirm safety and performance and update the clinical evaluation.

What is post market surveillance, and how is it different from PMCF?

Post market surveillance (PMS) is the manufacturer's whole system for collecting and reviewing experience with marketed devices, including complaints, trends and vigilance. PMCF is the part of PMS that proactively generates clinical data to update the clinical evaluation, and its plan sits inside the PMS plan.

Does the FDA require post market surveillance for medical devices?

Yes, in specific forms. The FDA can order Section 522 surveillance for certain class II and class III devices for up to 36 months, and it can require post approval studies as a condition of PMA or HDE approval. Mandatory adverse event reporting applies too, but there's no direct equivalent of the EU PMCF plan.

Is a PMCF survey enough, or do I need a PMCF study?

It depends on the evidence gap, the device class and the quality of data the survey can produce. In the MDCG 2020-6 hierarchy, general surveys rank 8, high quality surveys can reach rank 4, and high quality clinical investigations rank 1 or 2, so for class III and implantable devices a survey alone rarely closes the gap.

How often must the PMCF evaluation report be updated?

At least annually for class III and implantable devices, under MDR Article 61(11). For other devices the MDR sets no fixed interval, so the report follows the PMCF plan's schedule. Its main findings go into the PSUR, due at least every two years for class IIa and at least annually for class IIb and III (class I devices use a PMS report updated when necessary). A December 2025 Commission proposal would relax both rules, but it hasn't been adopted.

Is PMCF required for Class I or low risk devices?

Yes, by default. The MDR has no class based exemption: every PMS plan, Class I included, needs a PMCF plan or "a justification as to why a PMCF is not applicable" (Annex III 1.1(b)). Low risk devices often rely on a justification based on the device's risk, well established technology and sufficient existing clinical data, reasoned and documented in the technical documentation and sometimes paired with general activities such as literature screening and user feedback. It's much harder to sustain for class III and implantable devices.

What are the MDCG guidelines for PMCF plans?

MDCG 2020-7 (PMCF plan template) and MDCG 2020-8 (PMCF evaluation report template), both from April 2020, are the core. MDCG 2020-6 adds the evidence hierarchy for legacy devices, and MDCG 2025-10, from December 2025, is the MDCG's general guidance on post market surveillance.

Can PMCF data come from a patient registry?

Yes. "Evaluation of suitable registers" is a specific PMCF method named in Annex XIV Part B, and MDCG 2020-7 allows both manufacturer device registries and national public registries. The registry must be high quality, represent your device, stratify data appropriately and use endpoints that match the clinical evaluation.

Plan your PMCF data collection with WeGuide

See how eConsent, validated PROMs, registries and wearable data come together for MedTech outcome reporting and post market follow up.

Book a demo

No pressure, just a conversation.

Author
Written by
Thijs Sondag
Chief Product Officer

Behavioural Scientist. Experienced product manager in digital health. Over 10 years experience in the digital health field.

View full profile →
Fact checked by WeGuide Editorial Team

Questions we frequently get asked about this topic

Contact us
No items found.
Share the article
Become our partner
Ready to revolutionise your next clinical trial or healthcare project? We’d love to hear from you!
Get in touch
UP NEXT
Patient Registries and Real World Evidence